• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于表面等离子体共振的定量方法,用于评估c-Myc癌蛋白与DNA的结合以及小分子抑制剂对其结合的破坏作用。

A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors.

作者信息

Wang Huabo, Ramakrishnan Anand, Fletcher Steven, Prochownik Edward V

机构信息

Section of Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224, USA.

GE Healthcare, Piscataway, NJ 08854, USA.

出版信息

J Biol Methods. 2015;2(2). doi: 10.14440/jbm.2015.54.

DOI:10.14440/jbm.2015.54
PMID:26280010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4537179/
Abstract

The use of small molecules to interfere with protein-protein interactions has tremendous therapeutic appeal and is an area of intense interest. Numerous techniques exist to assess these interactions and their disruption. Many, however, require large amounts of protein, do not allow interactions to be followed in real time, are technically demanding or require large capital expenditures and high levels of expertise. Surface plasmon resonance (SPR) represents a convenient alternative to these techniques with virtually none of their disadvantages. We have devised an SPR-based method that allows the heterodimeric association between the c-Myc (Myc) oncoprotein and its obligate partner Max to be quantified in a manner that agrees well with values obtained by other methods. We have adapted it to examine the ability of previously validated small molecules to interfere with Myc-Max heterodimerization and DNA binding. These inhibitors comprised two distinct classes of molecules that inhibit DNA binding by preventing Myc-Max interaction or distorting pre-formed heterodimers and rendering them incapable of DNA binding. Our studies also point out several potential artifacts and pitfalls to be considered when attempting to employ similar SPR-based methods. This technique should be readily adaptable to the study of other protein-protein interactions and their disruption by small molecules.

摘要

使用小分子干扰蛋白质-蛋白质相互作用具有巨大的治疗吸引力,是一个备受关注的领域。存在多种技术来评估这些相互作用及其破坏情况。然而,许多技术需要大量蛋白质,不允许实时跟踪相互作用,技术要求高,或者需要大量资金投入和高水平专业知识。表面等离子体共振(SPR)是这些技术的一种便捷替代方法,几乎没有它们的缺点。我们设计了一种基于SPR的方法,该方法能够以与其他方法获得的值高度一致的方式对c-Myc(Myc)癌蛋白与其必需伴侣Max之间的异二聚体结合进行定量。我们对其进行了改进,以检测先前经验证的小分子干扰Myc-Max异二聚化和DNA结合的能力。这些抑制剂包括两类不同的分子,它们通过阻止Myc-Max相互作用或扭曲预先形成的异二聚体并使其无法结合DNA来抑制DNA结合。我们的研究还指出了在尝试采用类似的基于SPR的方法时需要考虑的几个潜在假象和陷阱。该技术应该很容易适用于研究其他蛋白质-蛋白质相互作用及其被小分子破坏的情况。

相似文献

1
A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors.一种基于表面等离子体共振的定量方法,用于评估c-Myc癌蛋白与DNA的结合以及小分子抑制剂对其结合的破坏作用。
J Biol Methods. 2015;2(2). doi: 10.14440/jbm.2015.54.
2
Intrinsically Disordered Regions in the Transcription Factor MYC:MAX Modulate DNA Binding via Intramolecular Interactions.转录因子MYC:MAX中的内在无序区域通过分子内相互作用调节DNA结合。
Biochemistry. 2024 Jan 24. doi: 10.1021/acs.biochem.3c00608.
3
Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc.小分子抑制剂在癌蛋白c-Myc上的多个独立结合位点。
J Am Chem Soc. 2009 Jun 3;131(21):7390-401. doi: 10.1021/ja900616b.
4
Small-molecule modulators of c-Myc/Max and Max/Max interactions.c-Myc/Max 和 Max/Max 相互作用的小分子调节剂。
Curr Top Microbiol Immunol. 2011;348:139-49. doi: 10.1007/82_2010_90.
5
Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.从c-Myc-Max异源二聚体亮氨酸拉链的1H-NMR溶液结构洞察异源二聚化机制。
J Mol Biol. 1998 Aug 7;281(1):165-81. doi: 10.1006/jmbi.1998.1914.
6
Max and c-Myc/Max DNA-binding activities in cell extracts.细胞提取物中的Max及c-Myc/Max DNA结合活性。
Oncogene. 1992 Sep;7(9):1783-92.
7
Small-molecule perturbation of competing interactions between c-Myc and Max.小分子干扰 c-Myc 和 Max 之间的竞争相互作用。
Bioorg Med Chem Lett. 2009 Feb 1;19(3):807-10. doi: 10.1016/j.bmcl.2008.12.025. Epub 2008 Dec 10.
8
Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.计算机辅助药物发现 Myc-Max 抑制剂作为治疗前列腺癌的潜在疗法。
Eur J Med Chem. 2018 Dec 5;160:108-119. doi: 10.1016/j.ejmech.2018.09.023. Epub 2018 Sep 11.
9
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts.Myc/Max二聚化的小分子拮抗剂可抑制Myc诱导的鸡胚成纤维细胞转化。
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3830-5. doi: 10.1073/pnas.062036999. Epub 2002 Mar 12.
10
Preferential heterodimeric parallel coiled-coil formation by synthetic Max and c-Myc leucine zippers: a description of putative electrostatic interactions responsible for the specificity of heterodimerization.合成的Max和c-Myc亮氨酸拉链优先形成异源二聚体平行卷曲螺旋:对负责异源二聚化特异性的假定静电相互作用的描述。
J Mol Biol. 1995 Dec 1;254(3):505-20. doi: 10.1006/jmbi.1995.0634.

引用本文的文献

1
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.MYC 癌基因:天然产物治疗癌症的可用药靶。
Aging Dis. 2024 Apr 1;15(2):640-697. doi: 10.14336/AD.2023.0520.
2
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.MYC:一种具有预后和治疗意义的多效癌基因,在血液恶性肿瘤中。
J Hematol Oncol. 2021 Aug 9;14(1):121. doi: 10.1186/s13045-021-01111-4.
3
Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.直接靶向 c-Myc 有助于安罗替尼的抗多发性骨髓瘤作用。

本文引用的文献

1
Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.通过合成α-螺旋模拟物干扰c-Myc-Max蛋白-蛋白相互作用。
J Med Chem. 2015 Apr 9;58(7):3002-24. doi: 10.1021/jm501440q. Epub 2015 Mar 30.
2
An overview of recent advances in structural bioinformatics of protein-protein interactions and a guide to their principles.蛋白质-蛋白质相互作用的结构生物信息学最新进展概述及其原理指南。
Prog Biophys Mol Biol. 2014 Nov-Dec;116(2-3):141-50. doi: 10.1016/j.pbiomolbio.2014.07.004. Epub 2014 Jul 29.
3
Evaluating protein-protein interaction (PPI) networks for diseases pathway, target discovery, and drug-design using 'in silico pharmacology'.
Cell Death Dis. 2021 Apr 14;12(4):396. doi: 10.1038/s41419-021-03685-w.
4
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc.去除癌症中的 Myc:直接抑制 c-Myc 的治疗策略。
Mol Cancer. 2021 Jan 4;20(1):3. doi: 10.1186/s12943-020-01291-6.
5
Inhibition of hepatocellular carcinoma by metabolic normalization.代谢重编程抑制肝癌
PLoS One. 2019 Jun 26;14(6):e0218186. doi: 10.1371/journal.pone.0218186. eCollection 2019.
6
OsMADS57 together with OsTB1 coordinates transcription of its target OsWRKY94 and D14 to switch its organogenesis to defense for cold adaptation in rice.OsMADS57 与 OsTB1 共同协调其靶基因 OsWRKY94 和 D14 的转录,以切换其器官发生为防御机制,从而适应水稻的低温。
New Phytol. 2018 Apr;218(1):219-231. doi: 10.1111/nph.14977. Epub 2018 Jan 24.
7
Diabetic Neuropathy and Gait: A Review.糖尿病神经病变与步态:综述
Diabetes Ther. 2017 Dec;8(6):1253-1264. doi: 10.1007/s13300-017-0295-y. Epub 2017 Sep 1.
8
Strategies to Inhibit Myc and Their Clinical Applicability.抑制Myc的策略及其临床应用
Front Cell Dev Biol. 2017 Feb 23;5:10. doi: 10.3389/fcell.2017.00010. eCollection 2017.
9
Kinetics and kinematics of diabetic foot in type 2 diabetes mellitus with and without peripheral neuropathy: a systematic review and meta-analysis.2型糖尿病伴或不伴周围神经病变患者糖尿病足的动力学和运动学:一项系统评价和荟萃分析
Springerplus. 2016 Oct 19;5(1):1819. doi: 10.1186/s40064-016-3405-9. eCollection 2016.
10
Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.雷公藤红素及雷公藤红素类三萜对c-Myc-Max异二聚体的直接抑制作用。
Oncotarget. 2015 Oct 20;6(32):32380-95. doi: 10.18632/oncotarget.6116.
使用“计算机药理学”评估疾病通路、靶点发现和药物设计的蛋白质-蛋白质相互作用(PPI)网络。
Curr Protein Pept Sci. 2014;15(6):561-71. doi: 10.2174/1389203715666140724090153.
4
Discovery of methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization.发现 4'-甲基-5-(7-硝基苯并[c][1,2,5]恶二唑-4-基)-[1,1'-联苯]-3-羧酸甲酯,一种 c-Myc-max 二聚体的小分子抑制剂的改良物。
ChemMedChem. 2014 Oct;9(10):2274-2285. doi: 10.1002/cmdc.201402189. Epub 2014 Jun 27.
5
Myc and its interactors take shape.Myc及其相互作用分子形成了特定形态。
Biochim Biophys Acta. 2015 May;1849(5):469-83. doi: 10.1016/j.bbagrm.2014.06.002. Epub 2014 Jun 14.
6
Protein-protein interactions and genetic diseases: The interactome.蛋白质-蛋白质相互作用与遗传疾病:相互作用组
Biochim Biophys Acta. 2014 Oct;1842(10):1971-1980. doi: 10.1016/j.bbadis.2014.05.028. Epub 2014 Jun 2.
7
Targeting of the MYCN protein with small molecule c-MYC inhibitors.用小分子 c-MYC 抑制剂靶向 MYCN 蛋白。
PLoS One. 2014 May 23;9(5):e97285. doi: 10.1371/journal.pone.0097285. eCollection 2014.
8
Small-molecule inhibitors of the Myc oncoprotein.Myc癌蛋白的小分子抑制剂。
Biochim Biophys Acta. 2015 May;1849(5):525-43. doi: 10.1016/j.bbagrm.2014.03.005. Epub 2014 Mar 19.
9
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.N- myc 癌基因:最大限度地利用其靶点、调控和治疗潜力。
Mol Cancer Res. 2014 Jun;12(6):815-22. doi: 10.1158/1541-7786.MCR-13-0536. Epub 2014 Mar 3.
10
Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5.利用小分子10074-G5的改良细胞穿透类似物破坏Myc-Max异二聚化。
Oncotarget. 2013 Jun;4(6):936-47. doi: 10.18632/oncotarget.1108.